Solventum reported second-quarter 2026 financial results with net sales of $2.2 billion, a 2.2% increase on a reported basis and a 9.5% increase organically. GAAP diluted earnings per share were $0.53, while adjusted diluted EPS rose 50.9% to $2.55. Operating cash flow reached $227 million and free cash flow was $144 million. The company announced its intent to separate its Health Information Systems business segment as part of a portfolio optimization strategy. Additionally, Solventum increased its full-year 2026 guidance for organic sales growth to +2.5% to +3.0%, adjusted EPS to $7.10–$7.20, and free cash flow to $200 million–$300 million. Solventum operates in the medical technology industry, providing advanced wound care, infection prevention, surgical solutions, dental products, and health information systems.

On August 5, 2026, Solventum Corporation announced its intention to pursue the separation of its Health Information Systems business as part of an ongoing portfolio optimization strategy. The company will evaluate various separation pathways, including a standalone spin-off or combination with a scaled player, targeting completion within 12 to 18 months. Health Information Systems generated $1.4 billion in annual sales for the twelve months ended December 31, 2025, and serves over 75% of U.S. hospitals. Solventum aims to emerge as a dedicated MedTech company focused on MedSurg and Dental Solutions solutions. The firm operates in the healthcare technology and medical devices industry.

Solventum Corporation appointed Neil Zieselman to the position of Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. Mr. Zieselman replaces Mary Wilcox, who is retiring. His compensation package includes a $130,000 cash sign-on bonus, a $500,000 annual long-term incentive target award, and an initial grant of $600,000 in restricted stock units. Solventum Corporation is a healthcare technology and medical solutions provider.